These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 22040280)
1. A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry. Kahook MY; Fechtner RD; Katz LJ; Noecker RJ; Ammar DA Curr Eye Res; 2012 Feb; 37(2):101-8. PubMed ID: 22040280 [TBL] [Abstract][Full Text] [Related]
2. Preservative content in generic and brand name glaucoma eye drops. Hallaji NA; Rao PP; Trope GE Can J Ophthalmol; 2016 Dec; 51(6):492. PubMed ID: 27938964 [No Abstract] [Full Text] [Related]
3. Effects of benzalkonium chloride- and polyquad-preserved combination glaucoma medications on cultured human ocular surface cells. Ammar DA; Noecker RJ; Kahook MY Adv Ther; 2011 Jun; 28(6):501-10. PubMed ID: 21603985 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart. Kim YI; Kim JH; Lee TY; Lee KW J Ocul Pharmacol Ther; 2015; 31(6):335-9. PubMed ID: 26133057 [TBL] [Abstract][Full Text] [Related]
5. Generic versus brand-name North American topical glaucoma drops. Mammo ZN; Flanagan JG; James DF; Trope GE Can J Ophthalmol; 2012 Feb; 47(1):55-61. PubMed ID: 22333853 [TBL] [Abstract][Full Text] [Related]
6. Effects of benzalkonium chloride- or polyquad-preserved fixed combination glaucoma medications on human trabecular meshwork cells. Ammar DA; Kahook MY Mol Vis; 2011; 17():1806-13. PubMed ID: 21750606 [TBL] [Abstract][Full Text] [Related]
7. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Ammar DA; Noecker RJ; Kahook MY Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366 [TBL] [Abstract][Full Text] [Related]
8. Determination of phosphate concentration in glaucoma eye drops commercially available in Spain. Martínez-Soroa I; de Frutos-Lezaun M; Ostra Beldarrain M; Egía Zurutuza A; Irastorza Larburu MB; Bachiller Cacho MP Arch Soc Esp Oftalmol; 2016 Aug; 91(8):363-71. PubMed ID: 27017538 [TBL] [Abstract][Full Text] [Related]
9. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034 [TBL] [Abstract][Full Text] [Related]
10. A comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and pulsatile ocular blood flow in primary open-angle glaucoma patients. Janulevicienë I; Harris A; Kagemann L; Siesky B; McCranor L Acta Ophthalmol Scand; 2004 Dec; 82(6):730-7. PubMed ID: 15606472 [TBL] [Abstract][Full Text] [Related]
11. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost. Tamer C; Oksüz H Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Stewart WC; Konstas AG; Nelson LA; Kruft B Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886 [TBL] [Abstract][Full Text] [Related]
13. Stability of latanoprost in generic formulations using controlled degradation and patient usage simulation studies. Velpandian T; Kotnala A; Halder N; Ravi AK; Archunan V; Sihota R Curr Eye Res; 2015 May; 40(6):561-71. PubMed ID: 25494824 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Lesk MR; Koulis T; Sampalis F; Sampalis JS; Bastien NR Ann Pharmacother; 2008 Apr; 42(4):498-504. PubMed ID: 18364402 [TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study. Chiseliţă D; Antohi I; Medvichi R; Danielescu C Oftalmologia; 2005; 49(3):39-45. PubMed ID: 16408674 [TBL] [Abstract][Full Text] [Related]
16. Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops. Ayaki M; Iwasawa A; Niwano Y Biocontrol Sci; 2012; 17(3):121-8. PubMed ID: 23007103 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Shin DH; Feldman RM; Sheu WP; Ophthalmology; 2004 Feb; 111(2):276-82. PubMed ID: 15019375 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma. Konstas AG; Kozobolis VP; Tersis I; Leech J; Stewart WC Eye (Lond); 2003 Jan; 17(1):41-6. PubMed ID: 12579169 [TBL] [Abstract][Full Text] [Related]
19. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost. Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of the latanoprost versus timolol/dorzolamide combination therapy in patients with primary open angle glaucoma. Rismanchian A; Eslami F; Moeini H; Attarzade H; Naderibeni A Saudi Med J; 2008 Mar; 29(3):384-7. PubMed ID: 18327364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]